Instil Bio, Inc. (TIL) intrinsic value & 10-year financials
Instil Bio, Inc. (TIL) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $5.91
- Market cap
- $39.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -15.7%
- Free cash flow (FY2025)
- —
TIL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$71.4M | -$10.70 | — | — | -58.5% |
| FY2024 | — | -$74.1M | -$11.39 | -$55.7M | — | -38.9% |
| FY2023 | — | -$156.1M | -$24.00 | -$102.7M | — | -58.5% |
| FY2022 | — | -$223.2M | -$1.72 | -$264.8M | — | -53.3% |
| FY2021 | $0 | -$156.8M | -$1.48 | -$180.0M | — | -30.1% |
| FY2020 | $138.0K | -$37.7M | -$2.36 | -$80.4M | -24379.7% | 144.7% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Instil Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Instil Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -15.7% ROIC.
Instil Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Instil Bio, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.